Literature DB >> 28591107

Industry 'road tests' new wave of immune checkpoints.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28591107     DOI： 10.1038/nbt0617-487

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  8 in total

1.  Immuno-oncology moves beyond PD-1.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

2.  Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Authors:  Bertram Bengsch; Andy L Johnson; Makoto Kurachi; Pamela M Odorizzi; Kristen E Pauken; John Attanasio; Erietta Stelekati; Laura M McLane; Michael A Paley; Greg M Delgoffe; E John Wherry
Journal:  Immunity       Date:  2016-08-02       Impact factor: 31.745

3.  Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors:  Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

4.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

5.  The epigenetic landscape of T cell exhaustion.

Authors:  Debattama R Sen; James Kaminski; R Anthony Barnitz; Makoto Kurachi; Ulrike Gerdemann; Kathleen B Yates; Hsiao-Wei Tsao; Jernej Godec; Martin W LaFleur; Flavian D Brown; Pierre Tonnerre; Raymond T Chung; Damien C Tully; Todd M Allen; Nicole Frahm; Georg M Lauer; E John Wherry; Nir Yosef; W Nicholas Haining
Journal:  Science       Date:  2016-10-27       Impact factor: 47.728

Review 6.  Inhibitory receptors as targets for cancer immunotherapy.

Authors:  Meghan E Turnis; Lawrence P Andrews; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2015-07       Impact factor: 5.532

Review 7.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

8.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Authors:  Chamutal Gur; Yara Ibrahim; Batya Isaacson; Rachel Yamin; Jawad Abed; Moriya Gamliel; Jonatan Enk; Yotam Bar-On; Noah Stanietsky-Kaynan; Shunit Coppenhagen-Glazer; Noam Shussman; Gideon Almogy; Angelica Cuapio; Erhard Hofer; Dror Mevorach; Adi Tabib; Rona Ortenberg; Gal Markel; Karmela Miklić; Stipan Jonjic; Caitlin A Brennan; Wendy S Garrett; Gilad Bachrach; Ofer Mandelboim
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745
  8 in total
  7 in total

1.  Adenosine checkpoint agent blazes a trail, joins immunotherapy roster.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2017-09-11       Impact factor: 54.908

Review 2.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

3.  Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.

Authors:  Xiaojie Yu; Xiao Huang; Xiuxiu Chen; Jianfei Liu; Chenglin Wu; Qian Pu; Yuxiao Wang; Xiaoqiang Kang; Lijun Zhou
Journal:  MAbs       Date:  2019-06-26       Impact factor: 5.857

4.  Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Authors:  Alberto L Horenstein; Antonella Chillemi; Roberta Zini; Valeria Quarona; Nicoletta Bianchi; Rossella Manfredini; Roberto Gambari; Fabio Malavasi; Davide Ferrari
Journal:  Front Pharmacol       Date:  2018-04-20       Impact factor: 5.810

5.  Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

Authors:  Wenchao Li; Niclas C Blessin; Ronald Simon; Martina Kluth; Kristine Fischer; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Björn Wellge; Tim Mandelkow; Nicolaus F Debatin; Laura Pott; Doris Höflmayer; Maximilian Lennartz; Guido Sauter; Jakob R Izbicki; Sarah Minner; Franziska Büscheck; Ria Uhlig; David Dum; Till Krech; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Eike Burandt; Stefan Steurer; Waldemar Wilczak; Andrea Hinsch
Journal:  BMC Cancer       Date:  2018-12-04       Impact factor: 4.430

6.  Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Authors:  Niclas C Blessin; Ronald Simon; Martina Kluth; Kristine Fischer; Claudia Hube-Magg; Wenchao Li; Georgia Makrypidi-Fraune; Björn Wellge; Tim Mandelkow; Nicolaus F Debatin; Doris Höflmayer; Maximilian Lennartz; Guido Sauter; Jakob R Izbicki; Sarah Minner; Franziska Büscheck; Ria Uhlig; David Dum; Till Krech; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Eike-Christian Burandt; Stefan Steurer; Waldemar Wilczak; Andrea Hinsch
Journal:  Dis Markers       Date:  2019-01-10       Impact factor: 3.434

7.  Expression of the immune checkpoint receptor TIGIT in seminoma.

Authors:  Andrea Hinsch; Niclas C Blessin; Ronald Simon; Martina Kluth; Kristine Fischer; Claudia Hube-Magg; Wenchao Li; Georgia Makrypidi-Fraune; Björn Wellge; Tim Mandelkow; Nicolaus F Debatin; Doris Höflmayer; Maximilian Lennartz; Guido Sauter; Jakob R Izbicki; Sarah Minner; Franziska Büscheck; Ria Uhlig; David Dum; Till Krech; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Eike Burandt; Stefan Steurer; Waldemar Wilczak
Journal:  Oncol Lett       Date:  2019-05-31       Impact factor: 2.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.